Editorial: Community series in hepatic immune response underlying liver cirrhosis and portal hypertension, volume II

Tian Lan; Sheyu Li; Haopeng Yu; Enis Kostallari; Jinhang Gao

doi:10.3389/fimmu.2023.1305666

Editorial: Community series in hepatic immune response underlying liver cirrhosis and portal hypertension, volume II

Front Immunol. 2023 Oct 11:14:1305666. doi: 10.3389/fimmu.2023.1305666. eCollection 2023.

Authors

Tian Lan^{1

2}, Sheyu Li³, Haopeng Yu⁴, Enis Kostallari⁵, Jinhang Gao^{1

2}

Affiliations

¹ Laboratory of Gastroenterology and Hepatology, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
² Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu, China.
³ Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu, China.
⁴ West China Biomedical Big Data Center, West China Hospital/West China School of Medicine, Sichuan University, Chengdu, China.
⁵ Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, United States.

No abstract available

Keywords: gut-liver axis; immune response; liver cirrhosis; liver immune microenvironment; macrophage; mesenchymal stem cell.

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

Humans
Hypertension, Portal* / etiology
Liver Cirrhosis*

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study was supported by the National Natural Science Fund of China (82322011, 82170625, and 82241054) and Gilead Research Scholar Award (EK). The authors declare that this study received funding from Gilead. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article, or the decision to submit it for publication.